Compare CAVA & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAVA | NUVL |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 8.3B |
| IPO Year | 2023 | 2021 |
| Metric | CAVA | NUVL |
|---|---|---|
| Price | $77.64 | $108.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 16 |
| Target Price | $91.00 | ★ $134.75 |
| AVG Volume (30 Days) | ★ 3.0M | 434.6K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $1,179,664,000.00 | N/A |
| Revenue This Year | $25.71 | N/A |
| Revenue Next Year | $20.57 | $1,239.49 |
| P/E Ratio | $413.40 | ★ N/A |
| Revenue Growth | ★ 22.41 | N/A |
| 52 Week Low | $43.41 | $71.14 |
| 52 Week High | $98.79 | $113.02 |
| Indicator | CAVA | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 41.53 | 61.49 |
| Support Level | $73.16 | $97.99 |
| Resistance Level | $89.60 | $112.61 |
| Average True Range (ATR) | 4.48 | 3.62 |
| MACD | -0.01 | 0.57 |
| Stochastic Oscillator | 33.45 | 96.28 |
Cava Group Inc owns and operates a chain of restaurants. It operates a Mediterranean-inspired fast-casual restaurant brand offering menu items. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: i) CAVA: It includes the operations of all company-owned CAVA restaurants, and ii) CAVA Foods: It includes the production of dips, spreads, and certain dressing bases used in CAVA restaurants as well as sales from the Company's consumer packaged goods business. The company generates the majority of its revenue from the CAVA segment.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.